{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:37:57Z","timestamp":1792715877481,"version":"4.5.0"},"reference-count":59,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.esmoop.2026.108582","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:05:47Z","timestamp":1790802347000},"page":"108582","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Delayed and long-delayed chemotherapy-induced nausea and vomiting in moderately emetogenic chemotherapy: a scoping review of reporting gaps"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3473-8244","authenticated-orcid":false,"given":"Y.","family":"Iimura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6195-8624","authenticated-orcid":false,"given":"R.","family":"Chow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5377-0901","authenticated-orcid":false,"given":"D.","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6183-4939","authenticated-orcid":false,"given":"T.","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3728-273X","authenticated-orcid":false,"given":"C.H.","family":"Ruhlmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6351-9991","authenticated-orcid":false,"given":"A.","family":"Molassiotis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4004-7834","authenticated-orcid":false,"given":"M.L.","family":"Affronti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Scott\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4171-454X","authenticated-orcid":false,"given":"H.","family":"Iihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2026.108582_bib1","doi-asserted-by":"crossref","first-page":"149","DOI":"10.6004\/jnccn.2012.0018","article-title":"Communicating about chemotherapy-induced nausea and vomiting: a comparison of patient and provider perspectives","volume":"10","author":"Salsman","year":"2012","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.esmoop.2026.108582_bib2","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.critrevonc.2015.12.001","article-title":"Impact of chemotherapy-induced nausea and vomiting on health-related quality of life and resource utilization: a systematic review","volume":"99","author":"Sommariva","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.esmoop.2026.108582_bib3","doi-asserted-by":"crossref","first-page":"4472","DOI":"10.1200\/JCO.2006.05.6382","article-title":"Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment","volume":"24","author":"Bloechl-Daum","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.108582_bib4","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1038\/bjc.1997.507","article-title":"Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists","volume":"76","author":"de Boer-Dennert","year":"1997","journal-title":"Br J Cancer"},{"key":"10.1016\/j.esmoop.2026.108582_bib5","article-title":"Chemotherapy-induced nausea and vomiting: pathogenesis, recommendations, and new trends","volume":"26","author":"Gupta","year":"2021","journal-title":"Cancer Treat Res Commun"},{"key":"10.1016\/j.esmoop.2026.108582_bib6","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s10549-013-2727-3","article-title":"Preference weights for chemotherapy side effects from the perspective of women with breast cancer","volume":"142","author":"Kuchuk","year":"2013","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.esmoop.2026.108582_bib7","first-page":"219","article-title":"Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer","volume":"13","author":"Sun","year":"2005","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.esmoop.2026.108582_bib8","doi-asserted-by":"crossref","first-page":"561","DOI":"10.2147\/PPA.S80327","article-title":"Patients\u2019 self-reported adherence to capecitabine on XELOX treatment in metastatic colorectal cancer: findings from a retrospective cohort analysis","volume":"9","author":"Kawakami","year":"2015","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.esmoop.2026.108582_bib9","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.3727\/096504017X15012905098071","article-title":"Self-reported adherence to capecitabine on XELOX treatment as adjuvant therapy for colorectal cancer","volume":"25","author":"Kawakami","year":"2017","journal-title":"Oncol Res"},{"key":"10.1016\/j.esmoop.2026.108582_bib10","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1200\/JCO.20.01296","article-title":"Antiemetics: ASCO guideline update","volume":"38","author":"Hesketh","year":"2020","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2026.108582_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.102195","article-title":"2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting","volume":"9","author":"Herrstedt","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.esmoop.2026.108582_bib12","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s10147-024-02535-x","article-title":"2023 Japan Society of Clinical Oncology clinical practice guidelines update for antiemesis","volume":"29","author":"Iihara","year":"2024","journal-title":"Int J Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108582_bib13","first-page":"45","article-title":"2023 updated MASCC\/ESMO Consensus recommendations: prevention of nausea and vomiting following moderately emetic risk antineoplastic agents","volume":"32","author":"Scott\u00e9","year":"2023","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.esmoop.2026.108582_bib14","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/j.ejca.2015.03.024","article-title":"Combination antiemetic therapy with aprepitant\/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): a multicentre, randomised, controlled phase 3 trial","volume":"51","author":"Nishimura","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2026.108582_bib15","article-title":"Effect of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in women: a randomized clinical trial","volume":"4","author":"Wang","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.esmoop.2026.108582_bib16","first-page":"4527","article-title":"Clinical Efficacy of Aprepitant in patients with gynecological cancer after chemotherapy using paclitaxel and carboplatin","volume":"35","author":"Maehara","year":"2015","journal-title":"Anticancer Res"},{"key":"10.1016\/j.esmoop.2026.108582_bib17","first-page":"1983","article-title":"Perception of healthcare providers versus patient reported incidence of chemotherapy-induced nausea and vomiting after the addition of NK-1 receptor antagonists","volume":"19","author":"Majem","year":"2011","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.esmoop.2026.108582_bib18","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s12032-018-1199-z","article-title":"Prophylactic aprepitant is better than salvage for carboplatin-based chemotherapy: a propensity score-matched analysis","volume":"35","author":"Karayama","year":"2018","journal-title":"Med Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108582_bib19","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s40780-021-00204-z","article-title":"Adding aprepitant to palonosetron does not decrease carboplatin-induced nausea and vomiting in patients with gynecologic cancer","volume":"7","author":"Watanabe","year":"2021","journal-title":"J Pharm Health Care Sci"},{"key":"10.1016\/j.esmoop.2026.108582_bib20","first-page":"73","article-title":"Prognostic role of chemotherapy-induced nausea and vomiting in recurrent ovarian cancer patients: results of an individual participant data meta-analysis in 1213","volume":"28","author":"Woopen","year":"2020","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.esmoop.2026.108582_bib21","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1080\/14796694.2025.2479417","article-title":"Nausea and vomiting in an evolving anticancer treatment landscape: long-delayed and emetogenic antibody-drug conjugates","volume":"21","author":"Park","year":"2025","journal-title":"Future Oncol"},{"key":"10.1016\/j.esmoop.2026.108582_bib22","first-page":"505","article-title":"Prevalence and predictors of long-delayed (> 120 h) chemotherapy-induced nausea and vomiting (CINV)-a systematic review and individual patient data meta-analysis","volume":"31","author":"Chow","year":"2023","journal-title":"Support Care Cancer"},{"issue":"8","key":"10.1016\/j.esmoop.2026.108582_bib23","first-page":"811","article-title":"Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC)","volume":"9","year":"1998","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2026.108582_bib30","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1093\/annonc\/mdg417","article-title":"Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron","volume":"14","author":"Gralla","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2026.108582_bib31","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1002\/cncr.11817","article-title":"Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron","volume":"98","author":"Eisenberg","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.esmoop.2026.108582_bib32","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1200\/JCO.2005.09.050","article-title":"Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy","volume":"23","author":"Warr","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.108582_bib33","first-page":"423","article-title":"Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study","volume":"18","author":"Rapoport","year":"2010","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.esmoop.2026.108582_bib34","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1093\/annonc\/mdv482","article-title":"Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trial","volume":"27","author":"Weinstein","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2026.108582_bib35","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1002\/cncr.30054","article-title":"Efficacy of the neurokinin-1 receptor antagonist rolapitant in preventing nausea and vomiting in patients receiving carboplatin-based chemotherapy","volume":"122","author":"Hesketh","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.esmoop.2026.108582_bib36","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/S1470-2045(15)00034-0","volume":"16","author":"Schwartzberg","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2026.108582_bib37","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s10147-015-0928-y","volume":"21","author":"Yahata","year":"2016","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.108582_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101480","article-title":"Aprepitant plus palonosetron versus dexamethasone plus palonosetron in preventing chemotherapy-induced nausea and vomiting in patients with moderate-emetogenic chemotherapy: a randomized, open-label, phase 3 trial","volume":"49","author":"Cheng","year":"2022","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.esmoop.2026.108582_bib39","doi-asserted-by":"crossref","first-page":"5807","DOI":"10.1002\/cncr.24630","volume":"115","author":"Arpornwirat","year":"2009","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.esmoop.2026.108582_bib40","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.lungcan.2015.11.009","article-title":"Evaluation of palonosetron and dexamethasone with or without aprepitant to prevent carboplatin-induced nausea and vomiting in patients with advanced non-small-cell lung cancer","volume":"90","author":"Kusagaya","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.esmoop.2026.108582_bib41","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1038\/bjc.2013.400","article-title":"A randomised, placebo-controlled, double-blind study of aprepitant in nondrinking women younger than 70 years receiving moderately emetogenic chemotherapy","volume":"109","author":"Tanioka","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.esmoop.2026.108582_bib42","doi-asserted-by":"crossref","first-page":"567","DOI":"10.3332\/ecancer.2015.567","article-title":"Comparative evaluation of triplet antiemetic schedule versus doublet antiemetic schedule in chemotherapy-induced emesis in head and neck cancer patients","volume":"9","author":"Kaushal","year":"2015","journal-title":"Ecancermedicalscience"},{"key":"10.1016\/j.esmoop.2026.108582_bib27","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.7150\/jca.87169","article-title":"Doublet or triplet antiemetic prophylaxis for nausea and vomiting induced by trastuzumab deruxtecan: an open-label, randomized, and multicenter exploratory phase 2 study","volume":"14","author":"Iihara","year":"2023","journal-title":"J Cancer"},{"key":"10.1016\/j.esmoop.2026.108582_bib28","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1007\/s10147-025-02748-8","article-title":"A multicenter randomized open-label phase 2 study investigating optimal antiemetic therapy for patients with advanced\/recurrent gastric cancer treated with trastuzumab deruxtecan: the EN-hance study","volume":"30","author":"Aoyama","year":"2025","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.108582_bib43","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1093\/annonc\/mdu101","article-title":"A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy","volume":"25","author":"Aapro","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2026.108582_bib25","doi-asserted-by":"crossref","first-page":"15769","DOI":"10.1002\/cam4.6121","article-title":"Single-dose NEPA versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy","volume":"12","author":"Zelek","year":"2023","journal-title":"Cancer Med"},{"key":"10.1016\/j.esmoop.2026.108582_bib44","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.26076","article-title":"Olanzapine as antiemetic prophylaxis in moderately emetogenic chemotherapy: a phase 3 randomized clinical trial","volume":"7","author":"Ostwal","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.esmoop.2026.108582_bib26","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.ygyno.2020.01.004","article-title":"Efficacy and safety of 5 mg olanzapine combined with aprepitant, granisetron and dexamethasone to prevent carboplatin-induced nausea and vomiting in patients with gynecologic cancer: a multi-institution phase II study","volume":"156","author":"Iihara","year":"2020","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.esmoop.2026.108582_bib45","doi-asserted-by":"crossref","first-page":"e1066","DOI":"10.1002\/onco.13772","article-title":"Low-dose olanzapine plus granisetron and dexamethasone for carboplatin-induced nausea and vomiting in patients with thoracic malignancies: a prospective multicenter phase II trial","volume":"26","author":"Sakai","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.esmoop.2026.108582_bib29","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.annonc.2024.09.001","volume":"36","author":"Sakai","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2026.108582_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.107801","article-title":"Mirtazapine plus granisetron and dexamethasone for carboplatin-induced nausea and vomiting in patients with thoracic cancers: a prospective multicenter phase II trial","volume":"192","author":"Iihara","year":"2024","journal-title":"Lung Cancer"},{"key":"10.1016\/j.esmoop.2026.108582_bib47","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1093\/annonc\/mdp584","article-title":"Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy","volume":"21","author":"Aapro","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2026.108582_bib48","first-page":"1217","article-title":"Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trial","volume":"19","author":"Celio","year":"2011","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.esmoop.2026.108582_bib49","first-page":"1139","article-title":"Risk factors associated with chemotherapy-induced nausea and vomiting in the triplet antiemetic regimen including palonosetron or granisetron for cisplatin-based chemotherapy: analysis of a randomized, double-blind controlled trial","volume":"27","author":"Tsuji","year":"2019","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.esmoop.2026.108582_bib50","first-page":"1171","article-title":"Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy","volume":"18","author":"Hesketh","year":"2010","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.esmoop.2026.108582_bib51","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s10147-015-0786-7","article-title":"Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan","volume":"20","author":"Tamura","year":"2015","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.108582_bib52","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/cas.12146","article-title":"Risk factors of chemotherapy-induced nausea and vomiting: index for personalized antiemetic prophylaxis","volume":"104","author":"Sekine","year":"2013","journal-title":"Cancer Sci"},{"key":"10.1016\/j.esmoop.2026.108582_bib53","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1200\/JCO.1997.15.1.116","article-title":"Determinants of postchemotherapy nausea and vomiting in patients with cancer. Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group","volume":"15","author":"Osoba","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.108582_bib54","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.annonc.2024.10.017","article-title":"Beyond the usual window: persistent nausea with trastuzumab deruxtecan calls for new management strategies","volume":"36","author":"Jordan","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2026.108582_bib55","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1200\/JCO.21.01315","article-title":"Randomized, double-blind, phase III study of fosnetupitant versus fosaprepitant for prevention of highly emetogenic chemotherapy-induced nausea and vomiting: CONSOLE","volume":"40","author":"Hata","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.108582_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115451","article-title":"Going beyond the 2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting","volume":"222","author":"Jordan","year":"2025","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2026.108582_bib57","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/clpt.2012.62","article-title":"Equivalent dynamic human brain NK1-receptor occupancy following single-dose i.v. fosaprepitant vs. oral aprepitant as assessed by PET imaging","volume":"92","author":"Van Laere","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.esmoop.2026.108582_bib58","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1007\/s12325-023-02474-5","article-title":"Fosnetupitant for the prevention of chemotherapy-induced nausea and vomiting: a short review and clinical perspective","volume":"40","author":"Abe","year":"2023","journal-title":"Adv Ther"},{"key":"10.1016\/j.esmoop.2026.108582_bib59","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1002\/cncr.34088","article-title":"A phase 3 safety study of fosnetupitant as an antiemetic in patients receiving anthracycline and cyclophosphamide: CONSOLE-BC","volume":"128","author":"Matsuura","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.esmoop.2026.108582_bib60","article-title":"Study protocol for a prospective observational study to evaluate the efficacy of fosnetupitant for long-delayed chemotherapy-induced nausea and vomiting in patients receiving platinum-based chemotherapy (LODEC-N)","volume":"13","author":"Iimura","year":"2023","journal-title":"J Clin Trials"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926025275?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926025275?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T23:41:57Z","timestamp":1792712517000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702926025275"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":59,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2059702926025275"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.108582","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Delayed and long-delayed chemotherapy-induced nausea and vomiting in moderately emetogenic chemotherapy: a scoping review of reporting gaps","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.108582","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"108582"}}